Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Exploring the role of EpCAM in HER2+ breast cancer tumorigenesis and metastasis
FY 2025-26
Summary
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of all breast cancers. HER2+ breast tumors are known to express HER2D16, a HER2 splice variant lacking a protein-coding region known as exon 16. Tumors expressing HER2D16 are known to be highly aggressive and associated with worse patient outcomes, although the mechanisms driving this phenomenon remain unknown. We have previously demonstrated that HER2D16 significantly upregulates epithelial cell adhesion molecule (EpCAM), an epithelial and tumor cell marker linked to cell adhesion, tumor initiation, and metastasis. Given this, we hypothesize that EpCAM contributes to the aggressive breast cancer phenotype as seen in HER2D16 tumor models. To investigate this, we have generated a novel HER2D16 mouse model with deletion of EpCAM in the mammary epithelium to assess whether EpCAM plays a role in breast tumor initiation and metastasis. Preliminary characterization shows that genetic loss of EpCAM significantly delays tumor onset and reduces tumor size in HER2D16 mouse models. We plan to investigate whether deleting EpCAM delays tumor initiation and progression through the downregulation of proteins involved in cell growth and proliferation. Previous studies have also linked EpCAM with breast cancer metastasis. Thus, we plan to use lung tissue from the HER2D16 mouse models to investigate whether EpCAM loss reduces the ability of the tumors to metastasize. Furthermore, human tissue samples of paired primary breast tumors and distant metastases will be used to validate this data clinically. Ultimately, these findings will provide meaningful insight into EpCAM's role in HER2+ breast cancer, laying the groundwork for its potential as a prognostic marker and therapeutic target.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572741
Name
Friendly Erin O
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the role of EpCAM in HER2+ breast cancer tumorigenesis and metastasis
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Breast Cancer; Cancer; Cell Adhesion; Epithelial Cell Adhesion Molecule (Epcam); Epithelial-Mesenchymal Transition (Emt); Genetically Engineered Mouse Models; Her2 Splice Isoform; Human Epidermal Growth Factor Receptor 2 (Her2); Metastasis; Tumorigenesis
Abstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of all breast cancers. HER2+ breast tumors are known to express HER2D16, a HER2 splice variant lacking a protein-coding region known as exon 16. Tumors expressing HER2D16 are known to be highly aggressive and associated with worse patient outcomes, although the mechanisms driving this phenomenon remain unknown. We have previously demonstrated that HER2D16 significantly upregulates epithelial cell adhesion molecule (EpCAM), an epithelial and tumor cell marker linked to cell adhesion, tumor initiation, and metastasis. Given this, we hypothesize that EpCAM contributes to the aggressive breast cancer phenotype as seen in HER2D16 tumor models. To investigate this, we have generated a novel HER2D16 mouse model with deletion of EpCAM in the mammary epithelium to assess whether EpCAM plays a role in breast tumor initiation and metastasis. Preliminary characterization shows that genetic loss of EpCAM significantly delays tumor onset and reduces tumor size in HER2D16 mouse models. We plan to investigate whether deleting EpCAM delays tumor initiation and progression through the downregulation of proteins involved in cell growth and proliferation. Previous studies have also linked EpCAM with breast cancer metastasis. Thus, we plan to use lung tissue from the HER2D16 mouse models to investigate whether EpCAM loss reduces the ability of the tumors to metastasize. Furthermore, human tissue samples of paired primary breast tumors and distant metastases will be used to validate this data clinically. Ultimately, these findings will provide meaningful insight into EpCAM's role in HER2+ breast cancer, laying the groundwork for its potential as a prognostic marker and therapeutic target.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Friendly, Erin O
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~